Journal of Molecular Oncology Research

About The Journal Open Access

Journal of Molecular Oncology Research

Molecular oncology refers to the process of tumor formation within the molecular level and its effects along with various therapeutic methods in the cancer treatment.

The Journal of Molecular Oncology Research (JMOR) is an international, peer reviewed journal that encourages high-quality original research, systematic reviews, meta-analyses and technology reports, perspectives on all disciplines and therapeutic areas within the specialty.

Aims and Scope

The journal aims to further research on broad spectrum of discoveries related to therapeutic advances in cancer treatment, molecular phenotypes, tumor diagnosis, cancer genetics, epigenetics, genomic instability, tumor immunology, chemotherapy, radiotherapy and surgery, etc. The principal criterion for publication is to establish a novel concept of clinical significance in diagnosis, prognosis and prevention strategies for cancer patients.

This multidisciplinary open access journal ensures wide spread dissemination of research work as original Research Articles, Review Article, Case Reports, Short Communication, Opinion Articles and Letter to Editor.

The journal prioritizes molecular analysis that provides novel mechanistic insight into pathways and processes linked to cancer risk, development, and/or progression. The journal emphasizes on all cancer-associated pathways (including cell-cycle regulation; cell death; chromatin regulation; DNA damage and repair; gene and RNA regulation; genomics; oncogenes and tumor suppressors; and signal transduction). For full consideration, primary research submissions must provide significant novel insight into existing pathway functions or address new hypotheses associated with cancer-relevant biologic questions.

The Journal is using Editor Manager System for easy online submission and tracking of the manuscript. To be acceptable for publication, an article should be positively considered by two individual reviewers followed by the Editor’s consent.

You may submit manuscripts online at www.editorialmanager.com/alliedacademies/ or as an email attachment to [email protected]

Please submit your manuscript to
[email protected]

Just Published Articles View More

Review Paper August 22, 2017

P.65-73

J Mol Oncol Res: 1(1): 65-73

Quantification of newer anticancer drug enzalutamide by stability indicating RP-LC method and UV-visible spectroscopic method in bulk and synthetic mixture.

Dharmendra J Prajapati*, Usmangani K. Chhalotiya, Minesh D. Prajapati, Jalpa U. Patel, Harsha V. Patel

Review Article August 09, 2017

P.1-11

J Mol Oncol Res: 1(1): 1-11

Hyperglycosylated hCG drives malignancy in cancer cases.

Laurence A. Cole

Case Blog August 07, 2017

P.5-6

J Mol Oncol Res: 1(1): 5-6

Acute tumor lysis syndrome after anti-pd-1 immunotherapy nivolumab for metastatic melanoma.

Daniel Brunnhoelzl and Jue Wang*

Research Article August 07, 2017

P.1-6

J Mol Oncol Res: 1(1): 1-6

EBV LMP1 regulates cancer growth through IRF-7 in nasopharyngeal carcinoma.

Jianguo Wu*, Dongsheng Xu, Qian Cheng, Luwen Zhang, Dan Cheng, Jing Zhao

Case Report August 07, 2017

P.1-2

J Mol Oncol Res: 1(1): 1-2

Melanoma associated with chronic leg ulcer: Case report.

Wilson Onuigbo*, Frank Akpuaka

Review Article August 07, 2017

P.1-23

J Mol Oncol Res: 1(1): 1-23

Human chorionic gonadotropin (hCG) and hyperglycosylated hCG, seven semi-independent critical molecules: A review.

Laurence A. Cole